Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial.

Adv Ther · 2025 · PMC11929685 · PMID 40025391

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Least square mean changes from baseline showed a trend towards improvement for the QLQ-C30 subscale of global health status and stabilization for physical functioning.

also in 53,322 other papers

an increasing trendno p-value reported

LS mean changes from baseline for the QLQ-C30 GHS/QoL indicated an increasing trend toward improvement from Cycle 3 onwards with a LS mean change of 3.6 (95% CI 0.8, 6.3) at Cycle 4 and larger changes (≥ 10 points) observed for patients on treatment at Cycles 10 and 12 [Cycle 12 LS mean 12.3 (95% CI 7.1, 16.6)].

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.